Investor Relations

Investor Relations

Myrexis, Inc. is a biotechnology company focused on the development of small molecule therapeutics with novel chemical structures and distinct mechanisms of action. The Company has generated a strong pipeline of differentiated product candidates in oncology and autoimmune diseases. Myrexis is focused on maximizing the therapeutic and commercial value of these molecules by developing potential first-in-class and/or best-in-class treatment options for patients with unmet needs.

Recent Releases

Feb 3, 2012
Myrexis to Hold Conference Call to Discuss Second Fiscal Quarter 2012 Financial Results

Nov 18, 2011
Myrexis Announces Corporate Reorganization to Focus on Development Objectives

View all releases »

Events & Presentations

Feb 9, 2012 at 4:30 PM ET
Myrexis Second Quarter FY 2012 Conference Call

View all events & presentations »

Stock Chart
Stock price graph
3 Mo.   6 Mo.   1 Yr.
Stock Quote
Myrexis, Inc.
Price: 2.76
Change: 0.00
Day High: 2.80
Day Low: 2.74
Volume: 45,800
Delayed at least 20 minutes.
Provided by eSignal.